EGFR-TKI靶向治疗肺癌的临床效果及对患者肿瘤标志物水平、肺功能指标的影响  

Clinical effect of EGFR-TKI targeted therapy on lung cancer and the impact on tumor marker level and pulmonary function

作　　者：宋春青 卢桂龙 郝玮 高正兴 赵丽波 陆汉红 宗嘉宝 韩磊 SONG Chunqing;LU Guilong;HAO Wei;GAO Zhengxing;ZHAO Libo;LU Hanhong;ZONG Jiabao;HAN Lei(Department of Oncology,People’s Hospital of Daxing District,Capital Medical University Daxing Teaching Hospital,Beijing 102600,China)

机构地区：[1]北京市大兴区人民医院/首都医科大学大兴教学医院肿瘤科

出　　处：《癌症进展》2019年第10期1184-1186,1190,共4页Oncology Progress

摘　　要：目的观察表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗肺癌的临床效果及对患者肿瘤标志物水平、肺功能指标的影响。方法根据治疗方式的不同将70例肺癌患者分为对照组和观察组,每组35例。对照组患者接受传统的化疗方案(紫杉醇+顺铂静脉化疗)进行治疗,观察组患者在对照组治疗方案的基础上接受EGFR-TKI靶向治疗。观察两组患者的总缓解率、肿瘤标志物水平、肺功能指标和不良反应发生情况。结果两组患者的总缓解率比较,差异无统计学意义(P﹥0.05)。治疗后,两组患者的神经元特异性烯醇化酶(NSE)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)和糖类抗原19-9(CA19-9)水平均低于本组治疗前(P﹤0.05),且观察组患者的NSE、CYFRA21-1和CA19-9水平均明显低于对照组患者(P﹤0.01)。对照组患者的不良反应总发生率为25.71%,观察组患者的不良反应总发生率为11.43%,两组比较,差异无统计学意义(P﹥0.05)。结论EGFR-TKI靶向治疗肺癌的临床疗效较好,可明显降低肺癌患者的肿瘤标志物水平,安全可靠,具有良好的临床应用价值。Objective To observe the effect of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFRTKI)targeted therapy on lung cancer and its influence on the level of tumor markers and lung function in patients with lung cancer.Method A total of 70 cases with lung cancer were included in the study as control group and study group according to respective treatment administered,with 35 cases in each.The control group received conventional chemotherapy(intravenous paclitaxel+cisplatin),while the study group was given EGFR-TKI targeted therapy additionally.The overall response rate,level of tumor markers,pulmonary function and incidence of adverse reactions were observed before and after treatment in both groups.Result There was no significant difference regarding the overall response rate between the two groups(P>0.05).After treatment,the level of neuron specific enolase(NSE),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)and carbohydrate antigen 19-9(CA19-9)in the two groups were decreased compared to that before treatment(P<0.05),and were significantly lower in study group in comparison with control group(P<0.01).There was no statistically significant difference between the overall incidence of adverse reactions in control group at 25.71%and in study group at 11.43%(P>0.05).Conclusion EGFR-TKI targeted therapy is clinically effective for the treatment of lung cancer,and may significantly reduce the level of tumor markers,demonstrating good safety.

关 键 词：肺癌 靶向治疗 肿瘤标志物 并发症 血细胞减少 

分 类 号：R734.2[医药卫生—肿瘤]